The quest for dementia prevention does not include an aspirin a day
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published March 25, 2020.
Article Versions
- Previous version (March 25, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- David S. Knopman, MD and
- Ronald C. Petersen, PhD, MD
- David S. Knopman, MD and
Consultant Bluefield project (frontotemporal dementia) ended 2018. DIAN study DSMB (Sept 2013 - July 2019).
NONE
NONE
Omsbudsman Neurology, previously; Scientific Integrity officer, currently
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) A4 clinical trial partially funded by Lilly (site PI) (2) Biogen Alzheimer Study (site PI)
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo AlzheimerÂs Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald C. Petersen, PhD, MD
NONE
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003
NONE
(1) Roche Incorporated, (2) Merck, (3) Genentech (DSMB), (4) Biogen, (5) GE Healthcare (presentation) (6) Eisai, Inc.
NONE
NONE
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) U01-AG024904 (PI) (2004-present) U01 AG016976 (PI) (1989 Â present) P30 AG062677 (2019 - present)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence
Dr. Knopman knopman{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Null Hypothesis
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive declineJoanne Ryan, Elsdon Storey, Anne M. Murray et al.Neurology, March 25, 2020 -
Articles
Metabolic syndrome and cognitive decline in French eldersThe Three-City StudyC. Raffaitin, C. Féart, M. Le Goff et al.Neurology, February 02, 2011 -
Article
Investigation of antihypertensive class, dementia, and cognitive declineA meta-analysisRuth Peters, Sevil Yasar, Craig S. Anderson et al.Neurology, December 11, 2019 -
Articles
Antiplatelet drugs in secondary prevention of strokeLessons from recent trialsHans-Christoph Diener et al.Neurology, November 01, 1997